title: Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.
abstract: The interactions among multiple pathogenetic mechanisms of diabetic peripheral neuropathy largely remain unexplored. Increased activity of aldose reductase, the first enzyme of the sorbitol pathway, leads to accumulation of cytosolic Ca²⁺, essentially required for 12/15-lipoxygenase activation. The latter, in turn, causes oxidative-nitrosative stress, an important trigger of mitogen activated protein kinase (MAPK) phosphorylation. This study therefore evaluated the interplay of aldose reductase, 12/15-lipoxygenase, and MAPKs in diabetic peripheral neuropathy. In experiment 1, male control and streptozotocin-diabetic mice were maintained with or without the aldose reductase inhibitor fidarestat, 16 mg kg⁻¹ d⁻¹, for 12 weeks. In experiment 2, male control and streptozotocin-diabetic wild-type (C57Bl6/J) and 12/15-lipoxygenase-deficient mice were used. Fidarestat treatment did not affect diabetes-induced increase in glucose concentrations, but normalized sorbitol and fructose concentrations (enzymatic spectrofluorometric assays) as well as 12(S)-hydroxyeicosatetraenoic concentration (ELISA), a measure of 12/15-lipoxygenase activity, in the sciatic nerve and spinal cord. 12/15-lipoxygenase expression in these two tissues (Western blot analysis) as well as dorsal root ganglia (immunohistochemistry) was similarly elevated in untreated and fidarestat-treated diabetic mice. 12/15-Lipoxygenase gene deficiency prevented diabetes-associated p38 MAPK and ERK, but not SAPK/JNK, activation in the sciatic nerve (Western blot analysis) and all three MAPK activation in the dorsal root ganglia (immunohistochemistry). In contrast, spinal cord p38 MAPK, ERK, and SAPK/JNK were similarly activated in diabetic wild-type and 12/15-lipoxygenase⁻/⁻ mice. These findings identify the nature and tissue specificity of interactions among three major mechanisms of diabetic peripheral neuropathy, and suggest that combination treatments, rather than monotherapies, can sometimes be an optimal choice for its management.
authors.affiliation: Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA.
authors.forename: Roman
authors.initials: R
authors.lastname: Stavniichuk
authors.forename: Hanna
authors.initials: H
authors.lastname: Shevalye
authors.forename: Hiroko
authors.initials: H
authors.lastname: Hirooka
authors.forename: Jerry L
authors.initials: JL
authors.lastname: Nadler
authors.forename: Irina G
authors.initials: IG
authors.lastname: Obrosova
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000818:Animals; D001092:Arachidonate 12-Lipoxygenase / Q000235:genetics / Q000378:metabolism*; D001093:Arachidonate 15-Lipoxygenase / Q000235:genetics / Q000378:metabolism*; D001786:Blood Glucose / Q000378:metabolism*; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology / Q000209:etiology* / Q000378:metabolism; D003929:Diabetic Neuropathies / Q000201:enzymology / Q000209:etiology* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005632:Fructose / Q000378:metabolism; D005727:Ganglia, Spinal / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D048289:Imidazolidines / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects; D010766:Phosphorylation; D012584:Sciatic Nerve / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D013012:Sorbitol / Q000378:metabolism*; D013116:Spinal Cord / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D013311:Streptozocin / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D048289:Imidazolidines; D005632:Fructose; D013012:Sorbitol; D013311:Streptozocin; C077139:fidarestat; D000449:Aldehyde Reductase; D001092:Arachidonate 12-Lipoxygenase; D001093:Arachidonate 15-Lipoxygenase; D020928:Mitogen-Activated Protein Kinases; D002118:Calcium